SEC Form 4 · accession 0001140361-15-001940

IDEXX LABORATORIES INC /DE · IDXX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jonathan W Ayers

Officer — Chairman, President & CEO · Director

Period of report

Jan 14, 2015

Accepted (ET)

Jan 15, 2015 · 5:22 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000874716

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 14, 2015	M	28,512	$28.655	A	459,642	D
Common Stock	Jan 14, 2015	S	100	$153.70	D	459,542	D
Common Stock^F3	Jan 14, 2015	S	4,200	$155.5162	D	455,342	D
Common Stock^F4	Jan 14, 2015	S	3,300	$156.0286	D	452,042	D
Common Stock^F5	Jan 14, 2015	S	1,593	$157.2315	D	450,449	D
Common Stock^F6	Jan 14, 2015	S	15,824	$158.3782	D	434,625	D
Common Stock^F7	Jan 14, 2015	S	3,495	$158.9854	D	431,130	D
Common Stock	holding	—	—		—	49,000	I	By Ayers Family Trust

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F8	$28.655	Jan 14, 2015	M	28,512	D	—	Feb 2, 2015	Common Stock	28,512	0	D

Explanation of responses

F1Includes 49 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 12/31/2014.
F2The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.
F3The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $154.765 to $155.75, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5, 6 and 7 to this Form 4.
F4The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.76 to $156.41, inclusive.
F5The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.855 to $157.72, inclusive.
F6The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $157.90 to $158.86, inclusive.
F7The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $158.91 to $159.00, inclusive.
F8Grant of options to buy shares of common stock that became exercisable as to 20,000 shares on 02/03/2006, 02/03/2007, 02/03/2008 and 02/03/2009, and the remaining 16,512 shares on 02/03/2010.